Denmark-based Genmab and Switzerland-based ADC Therapeutics have collaborated to jointly develop a new antibody-drug conjugate (ADC) product targeting multiple cancer indications.
The collaboration will focus on developing the ADC product by combining HuMax-TAC, Genmab’s high-affinity fully human antibody targeting CD25, and ADC’s PBD-based warhead and linker technology.
Genmab chief executive officer Dr Jan van de Winkel said; "We believe our unique HuMax-TAC antibody has optimal characteristics for creation of an ultra-potent antibody-drug conjugate when used in combination with ADC Therapeutics’ novel PBD-based warhead and linker technology, which employs an emerging class of highly potent anticancer agents."
As part of the partnership, both the companies will have an equal share in the product initially, with the preclinical development led and funded by ADC Therapeutics.
Genmab has an option to preserve equal ownership of the product and will not acquire any development costs prior to the submission of an IND application to conduct clinical studies on patients.
As the product is advanced into clinical development, a minimum of 25% ownership stake will be maintained by Genmab.
Further financial terms of the deal have not been disclosed.
ADC Therapeutics chairman Dr Peter Corr said the potency, optimised conjugation and pharmaceutical properties of the company’s warhead payload technology maintain activity in highly resistant cancers.
"Our pre-clinical data for this product indicate the potential for curative efficacy in highly resistant populations at low ADC doses of this product in several oncology indications, an area with critical unmet needs," Corr said.